<DOC>
	<DOCNO>NCT02888054</DOCNO>
	<brief_summary>This study assess bioequivalence ( BE ) Lesinurad/Allopurinol Fixed-Dose Combination ( FDC ) Tablets Coadministered Lesinurad Allopurinol Tablets Fed Healthy Adult Subjects</brief_summary>
	<brief_title>Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence</brief_title>
	<detailed_description>The study assess BE lesinurad/allopurinol 200/300 FDC tablet coadministered lesinurad allopurinol tablet feed state .</detailed_description>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Lesinurad</mesh_term>
	<criteria>Subject body mass index range 18 kg/m2 30 kg/m2 . Screening serum urate level â‰¤ 7.0 mg/dL . Asian subject positive test HLAB*5801 allele . History suspicion kidney stone . Estimated creatinine clearance , determine Screening , &lt; 90 mL/min calculate CockcroftGault formula use ideal body weight . Undergone major surgery within 3 month prior Screening . Donated blood experience significant blood loss ( &gt; 450 mL ) within 12 week prior Day 1or give plasma donation within 4 week prior Day 1 . Inadequate venous access unsuitable vein repeat venipuncture . Received strong moderate enzymeinducing drug product within 2 month prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>